According to epidemiological data, nearly half—or 47%—of people living in the European Union regularly experience mild to moderate headaches, back pain, toothache, menstrual pain, and other types of pain. This clearly demonstrates that physical discomfort is not merely an occasional occurrence but a part of everyday life for a significant proportion of the population. Although not always severe, recurring pain can have a considerable impact on quality of life. It can make it difficult to concentrate at work, reduce productivity, affect sleep quality, and often cause emotional distress.
“Our new medicine is the first pain reliever in Olpha’s new over-the-counter product portfolio and represents an important step in its continued development. We are systematically expanding the range of products available to patients while strengthening domestic pharmaceutical manufacturing and developing competitive products for the Baltic and European markets,” says Dr. chem. Juris Hmeļņickis, Chairman of the Management Board of Olpha.
The new product expands the company’s over-the-counter medicines segment, in which Olpha continues to develop accessible solutions for treating common everyday health conditions. It took three years from the initial concept to the launch of the new pain relief medicine in European pharmacies.
Following the change in majority ownership, Olpha significantly revised its development strategy, making expansion into Western markets a priority. Since then, the company has made substantial progress in expanding its product portfolio. A total of 46 products have been submitted for registration in Western markets, 35 of which have already been approved in European countries. Overall, the company has obtained 198 national marketing authorisations across European Union Member States and the United Kingdom. At the same time, it is expanding its portfolio of registered products in Ukraine, the Balkan countries, Georgia, and Mexico. Eight medicines from the new product portfolio have already been launched in Western markets.